SCHEMBL22234100

SCHEMBL22234100

N#Cc1ccc(-c2cc([N+](=O)[O-])c3ccccc3c2N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.51
▸ VCAM1 P19320 2/20 0.42
▸ HPRT1 P00492 1/20 0.39
▸ EIF4E P06730 1/20 0.39
▸ MERTK Q12866 2/20 0.38
▸ TDP1 Q9NUW8 5/20 0.38
▸ MAPT P10636 5/20 0.38
▸ IKBKB O14920 1/20 0.37
▸ TNKS O95271 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ S1PR4 O95977 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22233992 0.84 CTSB (0.61) CTSBHPRT1TDP1MAPTMEN1
SCHEMBL28327664 0.79 VCAM1 (0.45) VCAM1HPRT1EIF4EMERTKTDP1
SCHEMBL22233986 0.78 CTSB (0.51) CTSBTDP1MAPTMEN1KMT2A
SCHEMBL22234367 0.78 TNKS (0.40) TNKSMEN1KMT2AALDH1A1TSHR
SCHEMBL6981433 0.76 ALDH1A1 (0.65) VCAM1EIF4EMERTKTDP1MAPT
SCHEMBL22234248 0.75 CTSB (0.48) CTSBHPRT1TDP1MAPTMEN1
SCHEMBL15156444 0.74 TDP1 (0.45) VCAM1MERTKTDP1MAPTMEN1
SCHEMBL31521564 0.74 CTSB (0.55) CTSBHPRT1TDP1MAPTMEN1
SCHEMBL14366638 0.74 CASP3 (0.44) VCAM1EIF4EMERTKTDP1MAPT
SCHEMBL8687725 0.72 CTSB (0.77) CTSBHPRT1TDP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-10-22 — — US disclosed
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-04-14 — — US disclosed
WO-2020150446-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 CTSB 3717/4885VCAM1 254/4885HPRT1 3626/4885
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction KEAP1, NFE2L2, HMOX1 CTSB 3717/4885VCAM1 254/4885HPRT1 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback